Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling Jones SA; Scheller J; Rose-John SJ Clin Invest 2011[Sep]; 121 (9): 3375-83The successful treatment of certain autoimmune conditions with the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the beta-receptor subunit glycoprotein 130 (gp130). In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator. Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.|Animals[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/immunology/therapeutic use[MESH]|Autoimmune Diseases/drug therapy/immunology[MESH]|Cytokine Receptor gp130/*immunology[MESH]|Humans[MESH]|Inflammation/drug therapy/immunology[MESH]|Interleukin-6/*immunology[MESH]|Neoplasms/immunology[MESH]|Receptors, Interleukin-6/genetics/*immunology[MESH]|Signal Transduction/*immunology[MESH] |
